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BACKGROUnD
In comparison to other cancers, gliomas are locally invasive cancers that seldom metastasize. Glioma 
cells infiltrate brain parenchyma up to several centimeters from the tumor core. Therefore, their recur-
rence occurs at the margin of tumor resection in about 90% of patients (1). Significant effort is put 
into analyzing peritumoral regions to understand the mechanisms of glioma recurrence after surgery 
(1–4). Such studies are done on peritumoral biopsies collected either before or during surgery. This 
comment seems incidental but is critical.
SURGiCAL BRAin inJURY RESHApES THE pERiTUMORAL 
LAnDSCApE
A critical overlooked point in neurooncology is that brain surgery triggers a wound–healing– 
inflammatory process in the resection margins where residual glioma cells are. Glioma resection is 
lesional, and it generates dramatic rearrangements in the peritumoral brain region. The protumori-
genic role of wounds and the vicious connection between inflammation and cancer have long been 
established in other tissues (5, 6). Regarding brain tissue, we already know that in the minutes follow-
ing cortical and parenchymal incisions, surgical brain injury (SBI) induces (i) a burst of glutamate 
and ATP, (ii) the release of mutagenic reactive oxygen species, and (iii) an influx of blood clotting 
factors and serum components (7, 8). Fibroblasts, mesenchymal stem cells, and other blood-borne 
cells, including inflammatory cells, also invade the resection margin (7, 8). This in turn leads to a 
further release of cytokines and growth factors. Small ischemic areas around the resection cavity, 
which are an important driver for malignant progression, are also observed (9, 10). Hallmarks of this 
perilesional region include inflammation, angiogenesis, glial cell proliferation, reactive gliosis, and 
fibrosis (7, 8). Indeed, SBI reshapes the peritumoral landscape into a protumorigenic environment.
COnCLUSiOn
Peritumoral biopsies collected before or during surgery are not representative of the SBI-induced 
protumorigenic microenvironment. Hence, critical information is missing to understand and prevent 
tumor recurrence. Personalized medicine and targeted therapies must integrate new technologies to 
improve our understanding of the SBI zone. Considering the resection margins as peritumoral or as 
perilesional is more than a simple matter of vocabulary. It is a necessary paradigm shift to understand 
and treat glioma recurrence after surgery.
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